Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism*
- 26 May 1997
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 61 (5) , 509-517
- https://doi.org/10.1016/s0009-9236(97)90131-4
Abstract
We studied the genotypes of polymorphic N-acetyltransferase (NAT2) in 145 Japanese subjects by the polymerase chain reaction-restriction fragment length polymorphism method. The rapid-type NAT2*4 was expressed at a higher frequency (68.6%) than the slow-type genes with specific point mutations (NAT2*6A, 19.3%; NAT2*7B, 9.7%; NAT2*5B, 2.4%). The frequency of NAT2* genotypes consisted of 44% of a homozygote of NAT2*4, 49% of a heterozygote of NAT2*4 and mutant genes, and 7% of a combination of mutant genes. The metabolic activity for procainamide to N-acetylprocainamide was measured in 11 healthy subjects whose genotype had been determined. Although the acetylation activity substantially varied interindividually, the variability was considerably reduced after classification according to the genotype. The N-acetylprocainamide/procainamide ratio in urinary excretion was 0.60 +/- 0.17 (mean +/- SD) for those with NAT2*4/*4, 0.37 +/- 0.06 for NAT2*4/*6A, 0.40 +/- 0.03 for NAT2*4/*7B, and 0.17 for NAT2*6A/*7B. The results indicated that the NAT2* genotype correlates with acetylation of procainamide.Keywords
This publication has 33 references indexed in Scilit:
- Preliminary phenotypic map of chromosome 4p16 based on 4p deletionsAmerican Journal of Medical Genetics, 1995
- Genetic Analysis of the Arylamine N-Acetyltransferase Polymorphism in Breast Cancer PatientsOncology, 1995
- An improved method for genotyping ofN-acetyltransferase polymorphism by polymerase chain reactionJournal of Human Genetics, 1993
- The Structure and Characteristics of a Fourth Allele of Polymorphic N-Acetyltransferase Gene Found in the Japanese PopulationBiochemical and Biophysical Research Communications, 1993
- Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variantsPharmacogenetics, 1992
- Susceptibility in urinary bladder cancer: Acetyltransferase phenotypes and related risk factorsCancer Letters, 1986
- Population Pharmacokinetics of Procainamide from Routine Clinical DataClinical Pharmacokinetics, 1984
- Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotypeJournal of Pharmacokinetics and Biopharmaceutics, 1979
- Effect of Acetylator Phenotype on the Rate at Which Procainamide Induces Antinuclear Antibodies and the Lupus SyndromeNew England Journal of Medicine, 1978
- Kinetics of procainamide and N-acetylprocainamide in renal failureKidney International, 1977